
|Videos|August 1, 2022
EP. 9A: The Rationale for CDK4/6 Inhibition in ES-SCLC and Updates on Trilaciclib Clinical Trial Data
Author(s)Jerome H. Goldschmidt, MD
In the fifth interview of the series, medical oncologist and hematologist Dr. Jerome H. Goldschmidt from Blue Ridge Cancer Care elaborates on the rationale for use of CDK4/6 inhibitors such as trilaciclib for prevention of chemotherapy-induced myelosuppression (CIM) in extensive-stage small cell lung cancer (ES-SCLC), and touches on recently presented data on trilaciclib.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
3
Multiomic Real-World Data Predict Outcomes in Metastatic Breast Cancer
4
FDA Grants FTD to GPRC5D Bispecific LBL-034 for R/R Multiple Myeloma
5





























